Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPeach State Health Plan abatacept Coverage Update …
    Ask Trek AI about this page
    CurrentPeach State Health PlanPolicy CP.PHAR.241

    Clinical Policy: Abatacept (Orencia) Coverage Criteria

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy CP.PHAR.241 alerts

    Get alerted when Policy CP.PHAR.241 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, exclusions, dosing, and therapeutic alternatives for abatacept (Orencia) for Peach State Health Plan members across indicated conditions and provides appendices with scoring systems and dose rounding guidance.

    Policy Summary
    PayerPeach State Health Plan
    PolicyAbatacept (Orencia) coverage and administration
    Policy CodePolicy CP.PHAR.241
    Change TypeNo material changes
    Effective DateAug 16, 2024
    Next Review Date
    Key ActionProviders must obtain prior authorization and document weight and age to support weight‑based dosing; combination therapy with other bDMARDs or potent immunosuppressants is not authorized.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    IV & SCformulations / routes
    125 mgcommon adult SC dose
    1000 mgmax IV dose
    50/87.5/125 mgpediatric SC doses

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria — Indications, Dosing, and Exclusions

    Dosing / Administration

    Dosing regimens and maximum doses by indication and weight/age

    Adult IV dosing: Weight-based IV dose at weeks 0, 2, and 4, followed by every 4 weeks: Weight < 60 kg: 500 mg per dose; Weight 60 to 100 kg: 750 mg per dose; Weight > 100 kg: 1,000 mg per dose.see weight bands

    For RA: if a single IV loading dose is given, start first SC injection within one day of the IV dose.

    Adult SC dosing: SC: 125 mg once weekly.125 mg weekly

    Maximum SC dose listed as 125 mg/week.

    Pediatric SC dosing: Weight-based once weekly SC dosing: Weight 10 to < 25 kg: 50 mg once weekly; Weight 25 to < 50 kg: 87.5 mg once weekly; Weight ≥ 50 kg: 125 mg once weekly.pediatric weight bands

    pJIA-specific bands align with these pediatric SC doses.

    Pediatric IV dosing (pJIA/other): IV: weight-based dose at weeks 0, 2, and 4, followed by every 4 weeks. Examples: Weight < 75 kg: 10 mg/kg per dose; Weight 75 to 100 kg: 750 mg per dose; Weight > 100 kg: 1,000 mg per dose.weight-based mg/kg

    Maximum IV dose 1,000 mg every 4 weeks.

    aGVHD dosing: Age ≥ 6 years: 10 mg/kg (up to 1,000 mg maximum) on day before transplant, then Days 5, 14, and 28; Age ≥ 2 and < 6 years: 15 mg/kg on day before transplant, followed by 12 mg/kg on Days 5, 15, and 28. For patients ≥ 50 kg, SC listing notes 125 mg per dose.age and weight-specific

    Maximum dose 1,000 mg per dose.

    Coverage is limited to FDA‑approved indications and other uses explicitly addressed in this policy. Non‑FDA approved indications that are not listed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the Peach State off‑label use policy CP.PMN.53. Requests for off‑label uses without adequate supporting documentation may be denied.

    The policy explicitly prohibits combination therapy of abatacept with other biologic DMARDs or with Janus kinase inhibitors. This prohibition has been reiterated across policy sections (Sections I–III) and in recent reviews; requests for combination use with a bDMARD or a JAK inhibitor are not authorized and may be denied.

    Use of abatacept in combination with other biologic DMARDs or potent immunosuppressants is considered not authorized due to additive immunosuppression and increased risk of neutropenia and serious infections. Examples of agents that must not be used concurrently with abatacept include, but are not limited to, TNF antagonists (e.g., Cimzia, Enbrel, Humira and biosimilars, Remicade and biosimilars, Simponi), interleukin agents (e.g., Actemra, Arcalyst, Bimzelx, Cosentyx, Ilaris, Ilumya, Kevzara, Kineret, Omvoh, Siliq, Skyrizi, Spevigo, Stelara, Taltz, Tremfya), JAK inhibitors (e.g., Cibinqo, Olumiant, Rinvoq, Xeljanz), anti‑CD20 agents (e.g., Rituxan), integrin receptor antagonists (Entyvio), tyrosine kinase 2 inhibitors (Sotyktu), sphingosine‑1‑phosphate receptor modulators (Velsipity), and other selective co‑stimulation modulators. Concurrent administration with these agents is not authorized.

    Initial / Induction Therapy Requirements

    Initial/induction therapy

    Induction and pediatric/adult initial dosing per indication and weight:

    Adult IV induction: IV loading doses at weeks 0, 2, and 4: Weight < 60 kg: 500 mg; Weight 60–100 kg: 750 mg; Weight > 100 kg: 1,000 mg. Follow with IV every 4 weeks or transition to SC per regimen.per weight bands

    Follow indication-specific loading schedules.

    Adult SC initiation: Start SC weekly dosing: Adults: 125 mg once weekly. If a single IV loading dose is given for RA, begin the first SC injection within one day of the IV dose.125 mg weekly
    Pediatric SC initiation: Initiate SC once weekly by weight band: 10 to < 25 kg: 50 mg; 25 to < 50 kg: 87.5 mg; ≥ 50 kg: 125 mg.pediatric weight bands

    Document weight and age to support dosing.

    PJIA IV induction: IV at weeks 0, 2, and 4 then every 4 weeks: Weight < 75 kg: 10 mg/kg per dose; Weight 75–100 kg: 750 mg; Weight > 100 kg: 1,000 mg.per weight bands

    Maximum IV 1,000 mg every 4 weeks.

    aGVHD initial dosing: Per aGVHD regimen: Age ≥ 6 years: 10 mg/kg (up to 1,000 mg) on day before transplant, then Days 5, 14, and 28; Age 2–<6 years: 15 mg/kg day before transplant, then 12 mg/kg on Days 5, 15, and 28. For patients ≥ 50 kg, SC dose listing: 125 mg per dose.age and weight-specific

    Maximum 1,000 mg/dose.

    Initial Therapy

    Initial dosing regimens vary by indication, age, and weight.

    Initial IV loading: Administer IV weight-based loading doses at weeks 0, 2, and 4 for adults and where specified for pediatric indications (see weight bands).per weight bands

    Follow indication-specific loading schedules.

    Initial SC dosing: Initiate SC once weekly dosing according to age/weight band: Adults 125 mg once weekly; pediatrics per weight bands (50 mg, 87.5 mg, 125 mg).see pediatric/adult bands

    If IV loading given for RA, begin SC within one day.

    Maintenance and Continuation Therapy

    Maintenance dosing

    Maintenance dosing after initiation/induction:

    Maintenance dosing: IV maintenance: every 4 weeks at the weight‑based dose (up to 1,000 mg); SC maintenance: 125 mg once weekly for adults. Pediatric SC maintenance follows the weight bands listed above.

    See Appendix V/J for full regimens and pediatric dosing.

    Continuation Therapy

    Continued therapy considerations and historical updates

    Continued therapy notes: Historical updates removed certain prior continued-therapy documentation requirements (for example, minimum cJADAS-10 and specific response documentation). Providers should follow the current Section III continued therapy criteria and Appendix guidance for response documentation.see policy Section III

    Exact continued criteria and any removed items are documented in the policy revision history.

    Step Therapy and Therapeutic Alternatives

    StepRequirementNotes
    1Use of listed therapeutic alternatives (conventional DMARDs, TNF inhibitors, other biologics) may be preferred prior to initiation of abatacept (Orencia).Appendix B provides specific alternative agents and dosing regimens; some alternatives may not be formulary for all lines of business and may require prior authorization.
    StepRequirementNotes
    1Follow Section III step therapy and redirection rules (including use of preferred agents and biosimilars where required) before abatacept when applicable.Policy includes redirection and TNFi bypass rules (e.g., TNFi bypass if history of failure of two TNF blockers) and lists preferred adalimumab products and other redirect options in Section III and Appendix B.

    Coding and Billing Guidance

    HCPCS CodesHCPCS
    J0129Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
    inv-06: Weight-based dosing thresholds — Pediatric and adult weight cutoffs and bands
    Pediatric weight bands10 to <25 kg: 50 mg weekly; 25 to <50 kg: 87.5 mg weekly; ≥50 kg: 125 mg weekly
    Pediatric IV (pJIA) examples<75 kg: 10 mg/kg per dose; 75–100 kg: 750 mg per dose; >100 kg: 1,000 mg per dose (IV at weeks 0,2,4 then every 4 weeks)
    Adult IV bandsWeight <60 kg: 500 mg per dose; 60–100 kg: 750 mg per dose; >100 kg: 1,000 mg per dose (IV at weeks 0,2,4 then every 4 weeks)
    Adult SC band125 mg once weekly (maximum SC dose listed as 125 mg/week)
    aGVHD weight/age thresholdsWeight ≥50 kg: 125 mg per dose; age ≥6 years: 10 mg/kg (up to 1,000 mg) dosing schedule; age 2–<6 years: 15 mg/kg then 12 mg/kg on specified days

    Quantity Limits and Dosing Caps

    inv-24: abatacept (Orencia) — per dosing bands; IV up to 1000 mg per dose, SC up to 125 mg/week
    IV maximum per doseUp to 1,000 mg per dose (IV maintenance every 4 weeks)
    IV dosing by adult weightWeight <60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg (weeks 0,2,4 then every 4 weeks)
    SC dosing (adult)125 mg once weekly (SC) — commonly used adult dose
    Pediatric SC examples10 to <25 kg: 50 mg weekly; 25 to <50 kg: 87.5 mg weekly; ≥50 kg: 125 mg weekly
    Administration noteIf single IV loading dose given for RA, start first SC injection within one day of IV dose
    inv-25: Abatacept (Orencia) — per dosing band (e.g., 125 mg/week for SC; IV doses up to 1,000 mg every 4 weeks)
    SC standard maintenance125 mg once weekly (adult and pediatric ≥50 kg where applicable)
    IV maintenance frequencyEvery 4 weeks at weight‑based dose (up to 1,000 mg every 4 weeks)
    Example IV dosingAdults: <60 kg = 500 mg; 60–100 kg = 750 mg; >100 kg = 1,000 mg (weeks 0,2,4 then q4w)
    Quantity limit summaryPer dosing band: SC up to 125 mg/week; IV doses up to 1,000 mg every 4 weeks

    Provider Actions, Authorization & Documentation

    Prior Authorization

    Prior authorization required; combination use prohibited

    Prior authorization is required for abatacept and combination use with other biologic DMARDs or potent immunosuppressants is explicitly not authorized; requests for combination therapy will not be approved due to additive immunosuppression and increased infection risk.

    • Prior authorization required in alignment with formulary/non‑formulary and off‑label policies.
    • Combination use with bDMARDs or potent immunosuppressants (e.g., TNF antagonists, interleukin agents, JAK inhibitors, anti‑CD20 agents, integrin antagonists, TK2 inhibitors, S1P modulators) is not authorized.
    Billing Rule

    Coding/PA note — use J0129 under physician supervision

    When abatacept is administered under the direct supervision of a physician, report HCPCS code J0129 (injection, abatacept, 10 mg); note that code listing in the policy is informational and does not guarantee coverage — follow current professional coding guidance.

    • Use J0129 when drug is administered under direct physician supervision (not for self‑administered formulations).
    • Inclusion or exclusion of codes in this policy does not guarantee coverage; providers must reference up‑to‑date coding guidance when submitting claims.
    Step Therapy

    Therapeutic alternatives may be preferred and require PA

    Therapeutic alternatives listed in Appendix B may be preferred; some alternatives may themselves require prior authorization per formulary or line‑of‑business policies.

    • Appendix B provides a listing of preferred alternative therapies; these agents may not be formulary for all lines of business.
    • Some alternative drugs may require their own prior authorization per the applicable formulary (see CP.PMN.255/CP.PMN.16 as applicable).
    Step Therapy

    Follow step therapy/redirection rules in Section III

    Follow Section III step therapy and redirection rules when applicable; the policy includes redirection and TNFi bypass provisions that providers must follow during prior authorization review.

    • Policy contains redirection to other agents (e.g., Actemra, Olumiant) and TNFi bypass rules for members with prior failures per Section III.
    • Providers must follow Section III step and redirection requirements before abatacept when those rules apply.
    Prior Authorization

    Off‑label requests must follow CP.PMN.53 and include supporting documentation

    If the requested use is not listed in Section III and other formulary policies do not apply, providers must refer to the off‑label use policy CP.PMN.53 (for Medicaid) and supply sufficient documentation of efficacy and safety as required by that off‑label policy.

    • Requests for non‑FDA approved indications not addressed in this policy require documentation per CP.PMN.53.
    • Insufficient off‑label documentation may result in denial (see off‑label policy requirements).
    Documentation Required

    Document weight, age, and product formulation

    Document the patient’s weight and age and record the product formulation (vial, prefilled syringe, autoinjector) to support weight‑based IV dosing and pediatric SC dosing at the time of prior authorization and claim submission.

    • Provide weight and age to justify selection of the correct weight band (e.g., pediatric 10 to <25 kg, 25 to <50 kg, ≥50 kg; adult bands <60 kg, 60–100 kg, >100 kg).
    • Record the formulation used (single‑use IV vial vs prefilled syringe or autoinjector) since J0129 is not appropriate for self‑administered products.
    Denial Risk

    Non‑FDA/non‑listed uses without adequate documentation may be denied

    Requests for non‑FDA approved indications or other uses not addressed in the policy without sufficient supporting documentation may be denied per the off‑label use policy.

    • Non‑FDA indications not addressed in this policy require sufficient documentation of efficacy and safety per CP.PMN.53; lacking that, requests may be denied.
    • Combination use with other bDMARDs or potent immunosuppressants is explicitly not authorized and may be denied.
    Billing Rule

    Code listings are informational — verify coding guidance before claims

    Inclusion or exclusion of specific billing codes in this policy does not guarantee coverage; claims must follow current professional coding guidance and may be denied if coding rules are not followed.

    • Policy code listings are informational only; verify coding guidance before claim submission.
    • J0129 may be used for physician‑administered abatacept but is not for self‑administered formulations.

    Site of Care and Administration Setting

    Note

    IV administration expected in infusion setting; SC may be clinic or home

    IV abatacept dosing is weight‑based and expected to be given in an infusion setting; SC dosing may be given in clinic or at home per site rules.

    • IV administration implied by weight‑based IV dosing and expected in an infusion center.
    • SC dosing may be administered in clinic or at home.
    Billing Rule

    Report J0129 only for physician‑administered abatacept; not for self‑administered SC

    When abatacept is administered under direct physician supervision (e.g., infusion/office administration), report HCPCS J0129; do not report J0129 for self‑administered SC formulations.

    • Use J0129 only for physician‑administered drug.
    • Self‑administered SC products must not be billed with J0129.

    Biosimilar and Alternative Examples

    Note

    Preferred adalimumab products/biosimilars listed as redirect options

    Appendix and update notes list preferred adalimumab products and biosimilars (examples include Yusimry, Hadlima, adalimumab‑fkjp, adalimumab‑adbm, Simlandi, unbranded adalimumab‑aaty). Use of a preferred adalimumab product may be required as a redirect prior to abatacept for some indications.

    • Preferred adalimumab examples include Yusimry, Hadlima, adalimumab‑fkjp, adalimumab‑adbm, Simlandi, and unbranded adalimumab‑aaty.
    • Policy changes replaced previous redirection to Enbrel with requirement for use of one adalimumab product in some indications.

    Selected Abbreviations and Acronyms

    inv-16: Selected abbreviations / acronyms — DMARD, JAKi, MTX, PJIA etc.
    DMARDDisease-modifying antirheumatic drug
    JAKiJanus kinase inhibitors
    MTXMethotrexate
    PJIAPolyarticular juvenile idiopathic arthritis
    RA/PSARA = rheumatoid arthritis; PsA = psoriatic arthritis
    inv-17: Abbreviations — SC = subcutaneous; IV = intravenous; pJIA = polyarticular juvenile idiopathic arthritis
    SCSubcutaneous
    IVIntravenous
    pJIAPolyarticular juvenile idiopathic arthritis

    Background and Appendices

    Appendices to this policy include clinical scoring tools used to assess disease activity and support treatment decisions and continued therapy reviews. Included instruments are the ACR 2010 rheumatoid arthritis criteria, the CDAI, the RAPID3, and the cJADAS‑10. These tools and related appendices provide definitions (e.g., failure of methotrexate/DMARD), scoring thresholds, and guidance referenced elsewhere in the policy for initiation and continuation of abatacept.

    Policy Summary
    PayerPeach State Health Plan
    PolicyAbatacept (Orencia) coverage and administration
    Policy CodePolicy CP.PHAR.241
    Change TypeNo material changes
    Effective DateAug 16, 2024
    Next Review Date
    Key ActionProviders must obtain prior authorization and document weight and age to support weight‑based dosing; combination therapy with other bDMARDs or potent immunosuppressants is not authorized.
    SourceLink
    On This Page
    Coverage Criteria — Indications, Dosing, and ExclusionsInitial / Induction Therapy RequirementsMaintenance and Continuation TherapyStep Therapy and Therapeutic AlternativesCoding and Billing GuidanceQuantity Limits and Dosing CapsProvider Actions, Authorization & DocumentationSite of Care and Administration SettingBiosimilar and Alternative ExamplesSelected Abbreviations and AcronymsBackground and Appendices